Amanta Healthcare IPO Subscription Status

Amanta Healthcare IPO was subscribed 82.60 times on the final day of bidding (3rd September 2025, till 5:00 PM), showcasing an exceptional response from investors.

• Qualified Institutional Buyers (QIBs): 35.86x
• Non-Institutional Investors (NIIs): 209.40x
• Retail Individual Investors (RIIs): 54.96x

The company received bids for 57,81,83,634 shares against 70,00,000 shares on offer, highlighting strong oversubscription across all categories, especially among NIIs.

Day-wise subscription trend:

• Day 3: 82.60x
• Day 2: 19.63x
• Day 1: 4.62x

This steady surge indicates growing confidence from institutional and retail investors alike as the IPO progressed.

About Amanta Healthcare Limited

Founded in December 1994, Amanta Healthcare Limited is a well-established pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of sterile liquid products, primarily parenterals.

Product Portfolio Includes:

• IV fluids, diluents, and respiratory care solutions
• Eye drops and eye lubricants
• Irrigation solutions and essential medical aid products

The company uses advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies to ensure international quality standards in packaging.

Amanta Healthcare’s operations are supported by three business divisions:

1. National Sales (domestic markets)
2. International Sales (exports to regulated and semi-regulated markets)
3. Product Partnerships with both Indian and global pharma firms

The company markets 45+ generic products under its own brand and distributes them across India through a strong network of 320 distributors and stockists.

Workforce Strength: As of 31st March 2025, the company employs 1,718 professionals, including scientists, technicians, and support staff.

Amanta Healthcare Financial Report

• Revenue (FY 2025): ₹276 crores (vs ₹282 crores in FY 2024) → slight dip of ~2.1%
• Profit (FY 2025): ₹10.50 crores (vs ₹3.63 crores in FY 2024) → growth of ~189%

Despite a marginal revenue decline, the company significantly improved profitability, driven by better margins, cost efficiency, and higher demand for sterile products.

Amanta Healthcare IPO GMP

As of Wednesday, 3rd September 2025, the Grey Market Premium (GMP) stood at ₹13.

This indicates the IPO is trading at ₹139, compared to the issue price of ₹126, reflecting a premium of ~10.3% in the grey market.